Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to ...

EG110A is a non-replicating HSV-1 vector designed to selectively silence the signals of type C sensory neurons responsible ...

Novel capsid technology to enable convenient delivery in the doctor's office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease Ikarovec Ltd, which is devel ...

Researchers found that cold is detected differently in the skin than in internal organs. This split system helps explain why ...

A new method for engineering natural killer cells could make cancer immunotherapy more efficient, scalable, and affordable, ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Researchers have used precision-engineered nanoparticles to restore memory and clear hallmark brain plaques in mouse models of Alzheimer’s disease, a result that is already being described as a ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

Studienergebnisse DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies 23.12.2025 / 14:36 CET/CEST ...

In the expanding field of peptide-based research, a combination of two bioactive molecules—BPC‑157 and TB‑500—has garnered ...

News » DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...